{"id":14535,"date":"2026-08-23T10:35:06","date_gmt":"2026-08-23T10:35:06","guid":{"rendered":"https:\/\/www.incredmoney.com\/blog\/?p=14535"},"modified":"2026-08-25T10:38:25","modified_gmt":"2026-08-25T10:38:25","slug":"the-symbiotec-pharmalab-ipo","status":"publish","type":"post","link":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/","title":{"rendered":"The Symbiotec Pharmalab IPO: Natty or Juiced?"},"content":{"rendered":"

Symbiotec Pharmalab Limited is going for an IPO of \u20b91,757 Cr from August 24th to 27th, 2026. Symbiotec makes active pharmaceutical ingredients (APIs), mainly corticosteroids and steroidal hormones, and holds the largest global volume share in this segment.<\/em><\/p>\n

IPO Summary<\/h2>\n
\n
\n
\n\"\"<\/picture>\n<\/div>\n<\/figure>\n<\/div>\n
\n

 <\/p>\n<\/div>\n

Introduction<\/h2>\n

The global market for corticosteroid and steroidal-hormone active pharmaceutical ingredients is quite small and slow. Corticosteroid APIs (Active Pharmaceutical Ingredients) were worth $421 million in 2025, while steroidal-hormone APIs were worth ~$301 million.<\/p>\n

Few companies want to compete for a market this size. Symbiotec Pharmalab has decided to dominate it instead.<\/p>\n

Symbiotec holds a 38.2% global volume share in corticosteroid APIs and a 23.8% share in steroidal-hormone APIs. It is the\u00a0only company in the world<\/strong>, Indian or otherwise,\u00a0present across the top 10 products in both categories<\/strong>.<\/p>\n

In three individual molecules, Hydrocortisone, Testosterone and Methylprednisolone, its market share tops 75%. This means that, literally, their business is the whole market itself.<\/p>\n

Symbiotec is now going for an IPO consisting of a Fresh Issue of ~\u20b9150 Cr and an Offer for Sale of ~\u20b916,07. Cr from August 24 to 27, 2026.<\/p>\n

The Business Model<\/h2>\n

Symbiotec is a\u00a0research and manufacturing company<\/mark>\u00a0built on three connected platforms:<\/p>\n

    \n
  • organic chemistry,<\/li>\n
  • biotechnology, and<\/li>\n
  • complex injectables.<\/li>\n<\/ul>\n

    It uses these platforms to do two things.<\/p>\n

    First, it manufactures its own APIs and sells them to generic and specialty pharmaceutical companies.<\/p>\n

    Second, it manufactures products on contract for other companies, a business it calls CDMO, or contract development and manufacturing organisation.<\/p>\n

    The company follows a \u2018microbe-to-pharmacy\u2019 and \u2018farm-to-pharmacy\u2019 model.<\/p>\n

    Instead of buying finished chemical intermediates from outside suppliers<\/mark>, it makes many of its own key starting materials\u00a0in-house<\/mark>, through fermentation and multi-step chemical synthesis. This backward integration gives Symbiotec\u00a0control over cost and quality at each stage, and it reduces dependence on external suppliers for critical inputs<\/mark>.<\/p>\n

    Symbiotec earns the bulk of its revenue from selling its own APIs.\u00a0In FY26, API sales made up 96% of revenue<\/mark>.<\/p>\n

    The company has over 60 corticosteroid and steroidal-hormone APIs in its portfolio, sold to over 200 customers in more than 40 countries.<\/p>\n

    The\u00a0buyers\u00a0<\/strong>of Symbiotec\u2019s products are\u00a0pharmaceutical companies<\/mark>\u00a0who need a reliable, regulator-approved source of a hard-to-make ingredient. Its top five customers have been with the company for more than ten years on average,\u00a0a sign of how sticky their business is<\/mark>.<\/p>\n

    Symbiotec is extending its model in two directions.<\/p>\n

      \n
    • It has commissioned a new fermentation facility at Ujjain, aimed at biologics such as GLP-1 and insulin<\/li>\n
    • It has developed a complex injectables facility at Mhow, aimed at double-chamber vials and similar drug-device combinations.<\/li>\n<\/ul>\n

      Unit Economics (per \u20b9100 of Revenue)<\/h2>\n
      \n
      \n
      \n\"\"<\/picture>\n<\/div>\n<\/figure>\n<\/div>\n
        \n
      • Raw material cost<\/strong>\u00a0per \u20b9100 of revenue has fallen from \u20b944 in FY24 to \u20b935 in FY26, which is in fact tracking after a shift in sourcing away from China.<\/li>\n
      • Employee cost<\/strong>\u00a0per \u20b9100 of revenue has risen from \u20b915 to \u20b918, as the company staffed up new facilities at Ujjain and Mhow ahead of full commercial output.<\/li>\n
      • Adjusted EBITDA<\/strong>\u00a0per \u20b9100 of revenue has improved from \u20b924.91 to \u20b927.72 over FY24 to FY26, as a result of lower costs.<\/li>\n<\/ul>\n

        Operating Metrics<\/h2>\n
          \n
        • Revenue from the United States<\/strong>\u00a0tripled, from\u00a04% in FY25 to 13% in FY26<\/strong>. However, American tariffs pose the greatest risk to Symbiotec\u2019s business.\n
          \n
          \n
          \n\"\"<\/picture>\n<\/div>\n<\/figure>\n<\/div>\n<\/li>\n
        • China\u2019s share of Symbiotec\u2019s Total Expenses<\/strong>\u00a0has fallen sharply from\u00a053% in FY24 to 24% in FY26<\/strong>.<\/li>\n<\/ul>\n
          \n
          \n
          \n\"\"<\/picture>\n<\/div>\n<\/figure>\n<\/div>\n
            \n
          • Testosterone share<\/strong>\u00a0nearly doubled in two years, from 42% in FY24 to 76% in FY26, the sharpest gain of within Symbiotec\u2019s entire portfolio.<\/li>\n<\/ul>\n
            \n
            \n
            \n\"\"<\/picture>\n
            \n
            <\/div>\n<\/div>\n<\/div>\n<\/figure>\n<\/div>\n

            The Financial Stuff<\/h2>\n
            \n
            \n
            \n\"\"<\/picture>\n<\/div>\n<\/figure>\n<\/div>\n
              \n
            • Revenue from operations\u00a0<\/strong>grew from \u20b9716 Cr in FY24 to \u20b9869 Cr in FY26, a rise of ~21%, driven mainly by higher volumes.<\/li>\n
            • Adjusted EBITDA Margin\u00a0<\/strong>expanded each year, from 25% in FY24 to 28% in FY26, while\u00a0PAT Margin\u00a0<\/strong>stayed roughly the same.<\/li>\n
            • Finance Costs\u00a0<\/strong>more than tripled, from \u20b97 Cr in FY24 to \u20b925 Cr in FY26, as borrowed money funded new capacity. This is a big reason why PAT Margins fell even as Adj. EBITDA Margins rose.<\/li>\n<\/ul>\n

              Symbiotec\u2019s Peers (FY26)<\/h2>\n
              \n
              \n
              \n\"\"<\/picture>\n<\/div>\n<\/figure>\n<\/div>\n
                \n
              • Symbiotec\u2019s\u00a0EBITDA Margin\u00a0<\/strong>of 27% sits below every peer except Cohance Lifesciences.<\/li>\n
              • On\u00a0PAT Margin<\/strong>, Symbiotec at 13% trails Concord Biotech and Divi\u2019s Labs, but beats Cohance Lifesciences.<\/li>\n
              • Symbiotec is also the smallest company in the set by\u00a0revenue<\/strong>, at less than tenth the size of Divi\u2019s Laboratories and less than a sixth the size of Laurus Labs.<\/li>\n<\/ul>\n

                Key Risks<\/h2>\n
                  \n
                • Product concentration:<\/strong>\u00a0Symbiotec\u2019s top five products make up ~62% of revenue, and its top five customers also make up ~43%. Loss of demand for even a few of these products, or the loss of a single large customer, could have an outsized negative impact.<\/li>\n
                • Dependence on China:<\/strong>\u00a0China accounted for 24% of total expenses in FY26, down from a peak of 53% in FY24, but still a material share. Any disruption in Chinese supply, whether from trade restrictions or geopolitical tension would raise material costs.<\/li>\n
                • Regulatory and facility risk:<\/strong>\u00a0The US FDA concluded an inspection of the Pithampur facility on August 14, 2026 and issued four observations. Since API manufacturing depends on regulatory approval, serious adverse findings could disrupt supply.<\/li>\n<\/ul>\n

                  Conclusion<\/h2>\n
                  \n
                  \n

                  Symbiotec has built a dominant position in a small, slow-growing corner of the API market, and is now spending heavily to push into faster-growing biologics and complex injectables. The core API business is stable and sticky, but margins and returns on capital stand to improve still with respect to peers.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

                  Symbiotec Pharmalab Limited is going for an IPO of \u20b91,757 Cr from August 24th to 27th, 2026. Symbiotec makes active pharmaceutical ingredients (APIs), mainly corticosteroids and steroidal hormones, and holds the largest global volume share in this segment. IPO Summary   Introduction The global market for corticosteroid and steroidal-hormone active pharmaceutical ingredients is quite small […]<\/p>\n","protected":false},"author":2,"featured_media":14537,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[59],"tags":[2],"class_list":["post-14535","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","tag-blog"],"acf":[],"yoast_head":"\nThe Symbiotec Pharmalab IPO: Natty or Juiced? - InCred Money<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Symbiotec Pharmalab IPO: Natty or Juiced? - InCred Money\" \/>\n<meta property=\"og:description\" content=\"Symbiotec Pharmalab Limited is going for an IPO of \u20b91,757 Cr from August 24th to 27th, 2026. Symbiotec makes active pharmaceutical ingredients (APIs), mainly corticosteroids and steroidal hormones, and holds the largest global volume share in this segment. IPO Summary   Introduction The global market for corticosteroid and steroidal-hormone active pharmaceutical ingredients is quite small […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/\" \/>\n<meta property=\"og:site_name\" content=\"InCred Money\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-23T10:35:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-25T10:38:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/08\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1299\" \/>\n\t<meta property=\"og:image:height\" content=\"724\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Varun Shah\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Varun Shah\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/\"},\"author\":{\"name\":\"Varun Shah\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#\\\/schema\\\/person\\\/a994247d640675efd365664db35eac52\"},\"headline\":\"The Symbiotec Pharmalab IPO: Natty or Juiced?\",\"datePublished\":\"2026-08-23T10:35:06+00:00\",\"dateModified\":\"2026-08-25T10:38:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/\"},\"wordCount\":867,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp\",\"keywords\":[\"Blogs\"],\"articleSection\":[\"IPO\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/\",\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/\",\"name\":\"The Symbiotec Pharmalab IPO: Natty or Juiced? - InCred Money\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp\",\"datePublished\":\"2026-08-23T10:35:06+00:00\",\"dateModified\":\"2026-08-25T10:38:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#\\\/schema\\\/person\\\/a994247d640675efd365664db35eac52\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp\",\"contentUrl\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp\",\"width\":1299,\"height\":724},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/the-symbiotec-pharmalab-ipo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Symbiotec Pharmalab IPO: Natty or Juiced?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/\",\"name\":\"InCred Money\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/#\\\/schema\\\/person\\\/a994247d640675efd365664db35eac52\",\"name\":\"Varun Shah\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ff5f69fbbd06ef168df4fa372f8fc0cd81b33b554c7146dc0a6f25e9702f3860?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ff5f69fbbd06ef168df4fa372f8fc0cd81b33b554c7146dc0a6f25e9702f3860?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ff5f69fbbd06ef168df4fa372f8fc0cd81b33b554c7146dc0a6f25e9702f3860?s=96&d=mm&r=g\",\"caption\":\"Varun Shah\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/varun-shah-5b5570a4\\\/\"],\"url\":\"https:\\\/\\\/www.incredmoney.com\\\/blog\\\/author\\\/varunshah\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Symbiotec Pharmalab IPO: Natty or Juiced? - InCred Money","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/","og_locale":"en_US","og_type":"article","og_title":"The Symbiotec Pharmalab IPO: Natty or Juiced? - InCred Money","og_description":"Symbiotec Pharmalab Limited is going for an IPO of \u20b91,757 Cr from August 24th to 27th, 2026. Symbiotec makes active pharmaceutical ingredients (APIs), mainly corticosteroids and steroidal hormones, and holds the largest global volume share in this segment. IPO Summary   Introduction The global market for corticosteroid and steroidal-hormone active pharmaceutical ingredients is quite small […]","og_url":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/","og_site_name":"InCred Money","article_published_time":"2026-08-23T10:35:06+00:00","article_modified_time":"2026-08-25T10:38:25+00:00","og_image":[{"width":1299,"height":724,"url":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/08\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp","type":"image\/webp"}],"author":"Varun Shah","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Varun Shah","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#article","isPartOf":{"@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/"},"author":{"name":"Varun Shah","@id":"https:\/\/www.incredmoney.com\/blog\/#\/schema\/person\/a994247d640675efd365664db35eac52"},"headline":"The Symbiotec Pharmalab IPO: Natty or Juiced?","datePublished":"2026-08-23T10:35:06+00:00","dateModified":"2026-08-25T10:38:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/"},"wordCount":867,"commentCount":0,"image":{"@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/08\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp","keywords":["Blogs"],"articleSection":["IPO"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/","url":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/","name":"The Symbiotec Pharmalab IPO: Natty or Juiced? - InCred Money","isPartOf":{"@id":"https:\/\/www.incredmoney.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#primaryimage"},"image":{"@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/08\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp","datePublished":"2026-08-23T10:35:06+00:00","dateModified":"2026-08-25T10:38:25+00:00","author":{"@id":"https:\/\/www.incredmoney.com\/blog\/#\/schema\/person\/a994247d640675efd365664db35eac52"},"breadcrumb":{"@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#primaryimage","url":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/08\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp","contentUrl":"https:\/\/www.incredmoney.com\/blog\/wp-content\/uploads\/2026\/08\/cc012d60-a4ef-4782-b7bb-cd4a62c79b3c_1299x724.webp","width":1299,"height":724},{"@type":"BreadcrumbList","@id":"https:\/\/www.incredmoney.com\/blog\/the-symbiotec-pharmalab-ipo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.incredmoney.com\/blog\/"},{"@type":"ListItem","position":2,"name":"The Symbiotec Pharmalab IPO: Natty or Juiced?"}]},{"@type":"WebSite","@id":"https:\/\/www.incredmoney.com\/blog\/#website","url":"https:\/\/www.incredmoney.com\/blog\/","name":"InCred Money","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.incredmoney.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.incredmoney.com\/blog\/#\/schema\/person\/a994247d640675efd365664db35eac52","name":"Varun Shah","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ff5f69fbbd06ef168df4fa372f8fc0cd81b33b554c7146dc0a6f25e9702f3860?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ff5f69fbbd06ef168df4fa372f8fc0cd81b33b554c7146dc0a6f25e9702f3860?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff5f69fbbd06ef168df4fa372f8fc0cd81b33b554c7146dc0a6f25e9702f3860?s=96&d=mm&r=g","caption":"Varun Shah"},"sameAs":["https:\/\/www.linkedin.com\/in\/varun-shah-5b5570a4\/"],"url":"https:\/\/www.incredmoney.com\/blog\/author\/varunshah\/"}]}},"_links":{"self":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts\/14535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/comments?post=14535"}],"version-history":[{"count":3,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts\/14535\/revisions"}],"predecessor-version":[{"id":14539,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/posts\/14535\/revisions\/14539"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/media\/14537"}],"wp:attachment":[{"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/media?parent=14535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/categories?post=14535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.incredmoney.com\/blog\/wp-json\/wp\/v2\/tags?post=14535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}